China’s pharmaceutical industry is the fastest-growing pharmaceutical sector in the world, having grown by almost 17% per year over the past several decades. This industry produces Western medications and drugs, traditional Chinese medicines and treatments, medical and surgical equipment, materials used for hygiene and packing and many other products. Although challenges like lack of innovation and a declining number of firms beset the industry, efforts by the Chinese government and an increasing population are expected to fuel substantial further growth.
This month, EQUITIES Magazine looks at four Chinese pharmaceutical firms to may aid in boosting your portfolio: WUXI Pharmatech Inc. (NYSE: WX), Tongjitang Chinese Medicines Co. (NYSE: TCM), 3SBIO Inc. (NASDAQ: SSRX) and Simcere Pharmaceutical Group (NYSE: SCR). To read more of Anthony W. Haddad’s article about these firms and the opportunities in Chinese pharmaceuticals, go to page 50 of the upcoming digital issue of EQUITIES Magazine. To access this issue of the magazine and more, sign up for a free one-year subscription to EQUITIES Magazine.
About EQUITIES Magazine:
Since 1951, EQUITIES has served both retail and institutional investors by examining industry trends, analyzing strategies and opportunities, and profiling financial leaders and emerging public companies. Its global audience increased dramatically after the launch of its European and digital versions, as well as its website, which provides free real-time market quotes and a free customizable, real-time portfolio-management interface. EQUITIES is also one of a select group of publications available on the Apple iPhone.
